White Paper: What’s Next for Advanced Therapies?
The advanced therapies sector is growing exponentially. The Alliance for Regenerative Medicine (ARM) reports that the sector raised $23.1 billion in 2021 – a 16% year-over-year increase. That figure includes $1.9 billion in private financing and $9.8 billion in venture funding.
This white paper is based on a panel discussion sponsored by Precision ADVANCE at the 2021 Meeting on the Mesa conference and features insights from C-suite leaders on the current CGTx investment landscape, technology innovations, talent shortage and the evolution of reimbursement payment models.
- Anshul Mangal: President (Project Farma & Precision ADVANCE)
- R.A. Session II: President, Founder and CEO (Taysha Gene Therapies)
- Palani Palaniappan: EVP and CTO (Aruvant Sciences)
- Derrell Porter: Founder and CEO (Cellevolve Bio)
- Claudia Zylberberg: Founder and Executive Chair (Akron Bio)
- Phil Cyr: SVP (Precision Value & Health)
Conference: ASGCT Annual Meeting, 2022
Precision experts Travis Harrison: VP, Bioassay Solutions (Precision for Medicine), Reed Lyon: Director, Business Development (Precision for Medicine), and Pallavi Chhabra: Director, Business Development (Precision for Medicine) will be exhibiting at ASGCT Annual from May 16-19 in Washington, D.C. Travis Harrison will also be giving a presentation on, “Key Considerations for Design and Implementation of Nab Bioassays in Gene Therapy Development” on May 17 at 1PM EST.
Article: A Shared Opportunity – The Future of Cell and Gene Therapy
The commercialization of cell and gene therapies raises several complex conversations and questions for employers and payers. Without proper solutions and partnerships, employers and health insurers will be held responsible for extreme medical costs associated with gene therapy.
Article: Cell & Gene Therapies: Opportunities for Innovation
In recent years, the advanced therapy industry has been the most significant disruptor in medicine. Cell and gene therapies are transforming the way diseases are treated but are also aiming to cure entirely new patient populations. 2021 saw record-breaking investments across the board, with a 16% increase from the previous year, totaling $23.1billion raised. However, the question remains as to whether this will continue in 2022. As public markets adjust and the economy recovers in early 2022, investments in the cell and gene therapy space may plateau.
Conference: Meeting on the Med, 2022
Precision will be at this year’s Meeting on the Med conference from April 20 – 22nd in Barcelona, Spain. Connect with our team of experts as they lead meaningful discussions throughout this event, providing insights into the clinical development, manufacturing, and commercialization of cell and gene therapies.